Page 34 - Planegg News Today

Tim Demuth, M.D., Ph.D., has more than 20 years of broad leadership experience in drug development, with a focus in oncology MorphoSys AG (FSE: MOR; NASDAQ: MOR) announced today that Malte Peters

DGAP-News: MorphoSys AG / Key word(s): Miscellaneous MorphoSys appoints Tim Demuth as new Chief Research and Development Officer, fol...

DGAP-News: MorphoSys AG / Key word(s): Half Year Results MorphoSys AG Reports Second Quarter and First Half 2022 Financial Results ...

DGAP-News: MorphoSys AG / Key word(s): Half Year Results MorphoSys AG: Invitation to MorphoSys Second Quarter and First Half Year 202...

MorphoSys AG / Key word(s): Change in ForecastAd hoc: MorphoSys AG Reports Preliminary Q2 2022 Monjuvi U.S. Sales and Updates Financial Guidance for 202226-Jul-2022 / 11:10 CET/CESTDisclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Gr...

Preliminary Q2 2022 Monjuvi U.S. net product sales of US$ 23.3 million (€ 21.7 million)Update of financial guidance range for 2022 Monjuvi U.S. net product sales (now US$ 90 to US$ 110 million)Update of

Last month, Bayern Munich celebrated former team president Kurt Landauer’s crowning achievement — the club’s first national championship win in 1932.

Press release content from Business Wire. The AP news staff was not involved in its creation.

DGAP-News: MorphoSys AG / Key word(s): AgreementMorphoSys and HIBio Enter Into Equity Participation and License Agreements for Felzartamab and MOR210 14.06.2022 / 22:01 The issuer is solely responsible for the content of this announcement.Media ReleasePlanegg/Munich, Germany, South San Francisco, United States, June...

DGAP-News: MorphoSys AG / Key word(s): Agreement MorphoSys and HIBio Enter Into Equity Participation and License Agreements for Felza...